Scholarlink

<p>The complex pathological microenvironment of bone defects (resulting from trauma, tumors, or infections) poses significant clinical challenges, wherein adverse conditions (e.g., inflammation and vascular damage) impede bone regeneration and complicate treatment. Although bone grafting remains the primary clinical approach, its therapeutic efficacy is limited under these circumstances. To address this, we developed a gentiopicroside-strontium complex (GPS-Sr) to leverage the synergistic effects of both components, subsequently encapsulating it within a gelatin methacrylate (GelMA) hydrogel to create an injectable GelMA/GPS-Sr system with sustained-release properties. In vitrostudies demonstrated that GPS-Sr promotes osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) via the PI3K/AKT pathway, polarizes M2 macrophages to mitigate inflammation, and enhances angiogenesis. These in vitrofindings were corroborated in vivo, where the GelMA/GPS-Sr hydrogel significantly enhanced bone regeneration in a rat defect model, exhibiting high biocompatibility and achieving a ~ 45% increase in bone volume fraction (BV/TV) compared to the control group, along with a ~ 30% improvement over single-component formulations (GelMA/Sr or GelMA/GPS) at 8 weeks post-implantation. This strategy offers a promising therapeutic approach for complex bone repair.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An injectable multi-functional strontium based gentiopicroside hydrogel accelerates bone regeneration via immunomodulation and promoting osteo-/angiogenesis effects

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月6日

查看全文
  • Bin Xu,
  • Jian Zhao,
  • Jia Ming He,
  • Changcheng Chen,
  • Dongmei Yu,
  • Hao Wu,
  • Shuo Guo,
  • Yonghong Wu,
  • Ning Wang,
  • Hai Huang,
  • Zheng Guo

摘要

The complex pathological microenvironment of bone defects (resulting from trauma, tumors, or infections) poses significant clinical challenges, wherein adverse conditions (e.g., inflammation and vascular damage) impede bone regeneration and complicate treatment. Although bone grafting remains the primary clinical approach, its therapeutic efficacy is limited under these circumstances. To address this, we developed a gentiopicroside-strontium complex (GPS-Sr) to leverage the synergistic effects of both components, subsequently encapsulating it within a gelatin methacrylate (GelMA) hydrogel to create an injectable GelMA/GPS-Sr system with sustained-release properties. In vitrostudies demonstrated that GPS-Sr promotes osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) via the PI3K/AKT pathway, polarizes M2 macrophages to mitigate inflammation, and enhances angiogenesis. These in vitrofindings were corroborated in vivo, where the GelMA/GPS-Sr hydrogel significantly enhanced bone regeneration in a rat defect model, exhibiting high biocompatibility and achieving a ~ 45% increase in bone volume fraction (BV/TV) compared to the control group, along with a ~ 30% improvement over single-component formulations (GelMA/Sr or GelMA/GPS) at 8 weeks post-implantation. This strategy offers a promising therapeutic approach for complex bone repair.